Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methoxsalen solution - Therakos

Next Previous
Drug Profile

Methoxsalen solution - Therakos

Alternative Names: Methoxsalen sterile solution - Therakos; UVADEX

Latest Information Update: 05 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therakos
  • Developer Mallinckrodt Inc.; Therakos
  • Class Antineoplastics; Antipsoriatics; Coumarins; Psoralens; Small molecules
  • Mechanism of Action DNA cross linking agents; Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cutaneous T-cell lymphoma
  • Registered Graft-versus-host disease

Most Recent Events

  • 18 Dec 2025 Therakos withdrawn prior to enrolment the phase II EPIC trial in Colitis in the US (NCT06646016)
  • 28 Feb 2025 Therakos suspends a phase II trial in Colitis in USA prior to the enrolment due to the re-evaluation of the study design and strategy for expansion of trial by the sponsor(NCT06646016)
  • 17 Oct 2024 Therakos plans a phase II trial for Colitis (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) (Extracorporeal, Liquid), in January 2025 (NCT06646016) (MNK60052002)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top